Qudexy XR is indicated for initial or adjunctive therapy (treatment alone or with other medications or treatment options) in certain patients with partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome. It was approved by the FDA on March 11, 2014.
When will Qudexy XR be available to patients?
According to the manufacturer, Upsher-Smith, Qudexy XR will be available in the second quarter of 2014.
What strengths will be available, and how should it be taken?
Qudexy XR is available as an extended-release capsule in the following strengths: 25 mg, 50 mg, 100 mg, 150 mg, 200 mg. Depending on the dose your doctor decides is right for you, it should be taken once daily. The capsules may be swallowed whole or opened and sprinkled on a spoonful of soft food.
What are the common side effects of Qudexy XR?
The most common side effects associated with Qudexy XR include but are not limited to: tingling of the arms and legs, irregular eye movement, loss of appetite, nausea or indigestion, a change in the way foods taste, diarrhea, weight loss, nervousness, and upper respiratory tract infections.
Are there any other similar products currently available?
Yes. Trokendi XR is also an extended-release topiramate capsule available in 25 mg, 50 mg, 100 mg, and 200 mg strengths. However, it uses what is known as Microtrol technology. Microtrol technology uses uniquely engineered beads to deliver the medication consistently over a 24-hour period. More information on Trokendi XR can be found here.